Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

The activation of the cGAS-STING pathway has tremendous potential to improve anti-tumor
immunity by generating type I interferons. In recent decades, we have witnessed that …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Breast cancer has become the most commonly diagnosed cancer globally. The relapse and
metastasis of breast cancer remain a great challenge despite advances in chemotherapy …

In cancer, evolutionary forces select for clones that evade the immune system. Here we
analyzed> 10,000 primary tumors and 356 immune-checkpoint-treated metastases using …

Long non-coding RNAs (lncRNAs) are emerging as crucial regulators of gene expression
and physiological processes. LncRNAs are a class of ncRNAs of 200 nucleotides in length …

The period between" successful" treatment of localized breast cancer and the onset of
distant metastasis can last many years, representing an unexploited window to eradicate …

Background Breast cancer (BRCA) is the leading cause of cancer‐related death in women
worldwide. Pre‐and postoperative radiotherapy play a pivotal role in BRCA treatment but its …

Background The interface zone, area around invasive carcinoma, can be thought of as the
actual tissue of the tumor microenvironment with precedent alterations for tumor invasion …

The clinical outcome of patients with a diagnosis of hormone receptor (HR)+ breast cancer
has improved remarkably since the arrival of endocrine therapy. Yet, resistance to standard …